Biomarker & Intervention Discovery
Age-Related Macular Degeneration (AMD)
Pharmacologically actionable gene targets, therapeutic agents ranked by evidence tier, and active clinical trials.
NIH funding$96MFY2025 · RCDC estimate
Funding levelWell-Funded
Spontaneous remissionDry AMD: slow progressive loss; wet AMD progresses rapidly without treatment (50% of untreated reach legal blindness…
Best-intervention remissionAnti-VEGF (ranibizumab, aflibercept, bevacizumab): 30-40% vision gain in wet AMD (MARINA, ANCHOR trials); maintain…
Gap sizeLarge — treatment burden (monthly injections) is the primary barrier to adequate treatment in wet AMD; dry AMD has no…
Primary barrieraccess/biological
Full remission profile →
Remission & chronicity
Spontaneous remission
Dry AMD: slow progressive loss; wet AMD progresses rapidly without treatment (50% of untreated reach legal blindness within 2 years); no spontaneous remission of either form
Best-intervention remission
Anti-VEGF (ranibizumab, aflibercept, bevacizumab): 30-40% vision gain in wet AMD (MARINA, ANCHOR trials); maintain vision in 90%+ vs 62% in placebo; high-dose vitamin supplementation (AREDS2): 25% reduction in progression from intermediate to advanced dry AMD; port delivery system (Susvimo): 6-monthly refillable implant equivalent to monthly injections
Gap size
Large — treatment burden (monthly injections) is the primary barrier to adequate treatment in wet AMD; dry AMD has no proven disease-modifying treatment until 2023
Primary barrier
access/biological
Monthly anti-VEGF injection burden leads to under-treatment in real-world settings; 50% of wet AMD patients in routine care lose vision compared to 5-10% in trials; geographic atrophy (dry AMD) had no approved treatment until pegcetacoplan (Syfovre, 2023)
Biomarker Targets & Therapeutic Agents
Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC.
Agents ranked: ● Clinical >
● Mechanistic >
● Correlative.
Pipeline results not yet available. Run: python -m biomarker_pipeline.run_for_diseases --skip-llm
Clinical Trials
Recruiting and recently completed trials from ClinicalTrials.gov.
Data retrieved 2026-07-06.
No recent clinical trials found on ClinicalTrials.gov for this condition.
Agents Found By Disease-Level Search
Searched directly from “Age-Related Macular Degeneration (AMD)” via ClinicalTrials.gov interventions and Open Targets'
disease→drug data — independent of the 0-gene target panel above.
This surfaces agents whose mechanism doesn't route through a curated gene (combination
therapies, standard-of-care drugs, targets outside the panel).
Not yet run. python -m biomarker_pipeline.run_disease_agent_discovery --disease "..."